-
Product Insights
NewPrimary Immune Deficiency (PID) – Drugs In Development, 2024
Empower your strategies with our Primary Immune Deficiency (PID) – Drugs In Development, 2024 report and make more profitable business decisions. Primary immune deficiency (PID) is defined as weakened immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, and digestive problems such as cramping, loss of appetite, nausea, and diarrhea. The Primary Immune Deficiency (PID) drugs in development market research report...
-
Product Insights
NewNetherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) – Drugs In Development, 2024
Empower your strategies with our Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) – Drugs In Development, 2024 report and make more profitable business decisions. Netherton syndrome is a rare disorder affecting the skin, hair, and immune system. It is a severe, autosomal recessive form of ichthyosis associated with mutations in the SPINK5 gene, which encodes the serine protease inhibitor lympho-epithelial Kazal-type-related inhibitor (LEKTI). These mutations result in a dysfunctional protein that has a reduced capacity to inhibit serine proteases expressed in the...
-
Product Insights
NewTay-Sachs Disease – Drugs In Development, 2024
Empower your strategies with our Tay-Sachs Disease – Drugs In Development, 2024 report and make more profitable business decisions. Tay-Sachs disease is a rare, inherited metabolic disease that mostly affects young children and involves progressive damage to and death of cells, particularly in the brain. It is caused by a mutation in the enzyme hexosaminidase A, which allows the harmful buildup of lipids (fatty materials such as oils and acids) in cells. Both parents must carry the mutated gene in order...
-
Product Insights
NewFamilial Adenomatous Polyposis – Drugs In Development, 2024
Empower your strategies with our Familial Adenomatous Polyposis – Drugs In Development, 2024 report and make more profitable business decisions. Familial adenomatous polyposis  (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. It is caused by germline mutations in the APC gene. Symptoms include blood or mucus in the stools, diarrhea or constipation, weight loss due to unknown reason, and abdominal pain. Treatment includes surgery and medications such as non-steroidal...